Virtual Library
Start Your Search
Q.Y. Sun
Author of
-
+
P3.04 - Poster Session/ Biology, Pathology, and Molecular Testing (ID 235)
- Event: WCLC 2015
- Type: Poster
- Track: Biology, Pathology, and Molecular Testing
- Presentations: 1
- Moderators:
- Coordinates: 9/09/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P3.04-127 - Correlation Between ApoA-I and Prognosis of Advanced NSCLC Patients (ID 341)
09:30 - 09:30 | Author(s): Q.Y. Sun
- Abstract
Background:
To investigate the correlation between apolipoprotein A-I(ApoA-I)and clinicopathological features, as well as the effect of ApoA-I on the prognosis of advanced non-small cell lung cancer (NSCLC) patients.
Methods:
Retrospective analysis was performed for 117 cases with histologically confirmed IIIB and IV stage NSCLC patients in Changhai Hospital from January 2009 to December 2014. All patients were classified into two groups based on the value of baseline serum ApoA-I before treatment. The relationship between ApoA-I and clinicopathological features was studied. Univariate and multivariate analyses were performed to assess the prognostic effect of ApoA-I.
Results:
All patients were divided into two groups: low serum ApoA-I levels before treatment (≤1.2g/L, n=50,42.7%) and high serum ApoA-I levels before treatment (>1.2g/L, n=67,57.3%).ApoA-I was correlated with greatest tumor diameter（P=0.013), clinical stage(P=0.012),serum C-reactive protein before treatment（P=0.018),serum albumin(P<0.0001)and ECOG PS(P=0.024).The median survival time of low and high ApoA-I levels patients were10.1months and15.1 months, respectively,which indicated a statistically significant difference (χ2=7.027,P=0.008) between the two groups.Univariate analysis showed that smoking status（P=0.029), serum C-reactive protein before treatment（P=0.024),serum albumin（P=0.013),clinical stage(P=0.014),N stage（P=0.037）,ECOG PS（P=0.001)and serum ApoA-I levels before treatment（P=0.008).Multivariate analysis by using COX regression identified serum C-reactive protein before treatment（HR1.650，P=0.033),clinical stage（HR2.165，P=0.001), ECOG PS（HR0.451,P=0.008)and serum ApoA-I levels before treatment（HR0.487,P=0.005) as independent prognostic factors of all the patients.In addition, stratified analysis showed that the one-year survival rate of the low ApoA-I group was lower than that of the high ApoA-I group with or without distant metastasis, and the differences were statistically significant （χ2=12.053，P=0.001).
Conclusion:
An decreased serum ApoA-I levels before treatment indicates poor prognosis in advanced NSCLC patients. ApoA-I could be a potential biological marker for advanced NSCLC patients.
